Comparing Clinical Outcomes of TAVI vs Surgery for Small Aortic Annuli
- Recent analysis from the PARTNER 3 study has provided insights into the outcomes for patients with symptomatic severe aortic stenosis, regardless of annulus size.
- Similar Outcomes: Low-risk patients with small or large aortic annuli showed comparable 5-year outcomes with either balloon-expandable transcatheter aortic valve implantation (TAVI) or traditional surgery.
- Reintervention Rates: The need for additional aortic valve interventions was similar between TAVI and surgery, regardless of annulus size.
The SMART Trial and Answers for Balloon-Expandable Valves in Small Aortic Annuli
Table of Contents
Key Findings
Recent analysis from the PARTNER 3 study has provided insights into the outcomes for patients with symptomatic severe aortic stenosis, regardless of annulus size.
-
Similar Outcomes: Low-risk patients with small or large aortic annuli showed comparable 5-year outcomes with either balloon-expandable transcatheter aortic valve implantation (TAVI) or traditional surgery.
-
Reintervention Rates: The need for additional aortic valve interventions was similar between TAVI and surgery, regardless of annulus size.
- Quality of Life: Quality-of-life scores were consistent across treatment methods, indicating no significant advantage for one approach over the other in this aspect.
The SMART Trial Comparison
The SMART trial earlier suggested that self-expanding devices might have an advantage over balloon-expandable devices for patients with small aortic annuli. With balloon-expandable valves, patients experienced higher gradients and valve dysfunction rates at one year compared to self-expandable options.
Dr. Howard Herrmann, a lead investigator, highlighted concerns about long-term clinical outcomes for patients with balloon-expandable valves due to these findings.
PARTNER 3 Detailed Findings
- The PARTNER 3 study involved 925 patients, with 293 having small aortic annuli (≤ 430 mm²).
- Among small annulus patients:
- TAVI had a 5-year event rate of 21.2% for death, stroke, or rehospitalization.
- Surgical patients had a 31.6% event rate (P = 0.06), indicating a non-significant but favorable trend for TAVI.
- In patients with large annuli, rates were 23.5% for TAVI and 25.5% for surgery (P = 0.33).
- There were no differences in valve failure or reintervention needs across both approaches.
Dr. Madhavan mentioned that outcomes for TAVI appear to be promising, asserting that patients with small annuli can expect comparable outcomes to surgery.
Ongoing Debates and Research
Discussions continue regarding the optimal treatment for small aortic annuli, which is especially crucial for female patients, who tend to have smaller annuli.
Key questions include:
- Is the effective orifice area equivalent post-procedure in TAVI versus surgery?
- How do pressure gradients influence patient outcomes?
Ongoing research aims to address these questions and further clarify the benefits and risks associated with different valve types.
Latest Innovations
The Sapien Ultra Resilia valve has shown improved performance metrics over previous iterations and is under comparison with the Evolut FX valve, which remains advantageous in certain hemodynamic measures. However, improvements in the Resilia design are closing the gap in outcomes between these two types of valves.
Conclusion
The PARTNER 3 data provides reassurance for patients with small aortic annuli. Both TAVI and surgery yield similar outcomes in low-risk patients. Ongoing research continues to refine approaches to treatment, focusing on enhancing patient care and outcomes in this specialized area.